It was reported that APOD was significantly downregulated in hepatocellular carcinoma, colorectal cancer, epithelial ovarian cancer, and breast cancer, and was closely associated with tumor progression and poor prognosis in these cancer types [14,15,16,17]. Here, APOD is linked to neoplasm.